The Rudolf Virchow Center (RVZ) is the DFG Research Center for Experimental Biomedicine of the University of Würzburg. The Center was established in January 2002 as one of three pilot projects approved in 2001 by the DFG part of their plan to support national Centers of Excellence. Its founding chairman is Martin J. Lohse, a former co-worker of Robert Lefkowitz at Duke University. The center derives its name from the pathologist Rudolf Virchow, who was a professor in Würzburg from 1849 to 1856 and was the first to postulate that diseases originated in dysfunctions of cells. The primary goal of the Rudolf Virchow Center is to conduct excellent research. However, to ensure a continued influx of competent scientists, the Center is also committed to educating the next generation of researchers. The Rudolf Virchow Center has also initiated its own undergraduate and postgraduate programs, in cooperation with the Faculties of Biology and Medicine, namely the BSc/MSc program in Biomedicine and the Virchow Graduate Program that is part of the Graduate School of Life Sciences. The Rudolf Virchow Center is based on different columns. The main area research comprises Junior Research Groups, the Core Center, Research and Senior Professorship as well as the Bio-Imaging Center. In addition the RVZ Network offers funding for collaborations within the center or with researchers at the University. The Rudolf Virchow Center consists of more than 200 members. It aims to train and prepare a small group of students for research in the highly interdisciplinary field of biomedicine. To improve graduate-level education, the Rudolf Virchow Center established its own Virchow Graduate Program. Research is organized in four fields: Protein structure and function, Proteins in cellular signalling, Nucleic acid-binding proteins and Proteins in cell-cell interactions. Although each group has its own research focus, many projects are carried out in interdisciplinary collaborations providing different technologies or complementary biomedical expertise. Currently, the scientists are working on a variety of diseases such as cancer, cardiovascular, neurological or inflammatory disorders, at the molocular level. The groups all employ state-of-the-art technologies to focus on problems directly related to human disease.